Carmell Therapeutics Stock Buy Hold or Sell Recommendation
| CTCX Stock | 0.25 0.01 4.17% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Carmell Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Carmell Therapeutics given historical horizon and risk tolerance towards Carmell Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Carmell Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Carmell Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Carmell Stock please use our How to Invest in Carmell Therapeutics guide. In addition, we conduct extensive research on individual companies such as Carmell and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Carmell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Carmell |
Execute Carmell Therapeutics Buy or Sell Advice
The Carmell recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Carmell Therapeutics. Macroaxis does not own or have any residual interests in Carmell Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Carmell Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Carmell Therapeutics Trading Alerts and Improvement Suggestions
| Carmell Therapeutics generated a negative expected return over the last 90 days | |
| Carmell Therapeutics has high historical volatility and very poor performance | |
| Carmell Therapeutics has some characteristics of a very speculative penny stock | |
| Carmell Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (15.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Carmell Therapeutics generates negative cash flow from operations | |
| Carmell Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 34.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Meteora Capital, LLC Reduces Stake in Carmell Corp |
Carmell Therapeutics Returns Distribution Density
The distribution of Carmell Therapeutics' historical returns is an attempt to chart the uncertainty of Carmell Therapeutics' future price movements. The chart of the probability distribution of Carmell Therapeutics daily returns describes the distribution of returns around its average expected value. We use Carmell Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Carmell Therapeutics returns is essential to provide solid investment advice for Carmell Therapeutics.
| Mean Return | -0.73 | Value At Risk | -18.18 | Potential Upside | 18.52 | Standard Deviation | 14.01 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Carmell Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Carmell Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Carmell Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Carmell Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Carmell stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.58 | |
β | Beta against Dow Jones | 6.91 | |
σ | Overall volatility | 14.19 | |
Ir | Information ratio | -0.06 |
Carmell Therapeutics Volatility Alert
Carmell Therapeutics is displaying above-average volatility over the selected time horizon. Carmell Therapeutics is a potential penny stock. Although Carmell Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Carmell Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Carmell instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Carmell Therapeutics Fundamentals Vs Peers
Comparing Carmell Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Carmell Therapeutics' direct or indirect competition across all of the common fundamentals between Carmell Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Carmell Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Carmell Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Carmell Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Carmell Therapeutics to competition |
| Fundamentals | Carmell Therapeutics | Peer Average |
| Return On Equity | -1.76 | -0.31 |
| Return On Asset | -0.85 | -0.14 |
| Operating Margin | (96.71) % | (5.51) % |
| Current Valuation | 4.78 M | 16.62 B |
| Shares Outstanding | 20.91 M | 571.82 M |
| Shares Owned By Insiders | 33.66 % | 10.09 % |
| Shares Owned By Institutions | 19.49 % | 39.21 % |
| Number Of Shares Shorted | 505.09 K | 4.71 M |
| Price To Book | 1.91 X | 9.51 X |
| Price To Sales | 416.58 X | 11.42 X |
| EBITDA | (15.19 M) | 3.9 B |
| Net Income | (15.45 M) | 570.98 M |
| Total Debt | 2.14 M | 5.32 B |
| Book Value Per Share | 1.07 X | 1.93 K |
| Cash Flow From Operations | (8.35 M) | 971.22 M |
| Short Ratio | 0.04 X | 4.00 X |
| Earnings Per Share | 0.48 X | 3.12 X |
| Number Of Employees | 9 | 18.84 K |
| Beta | 0.31 | -0.15 |
| Market Capitalization | 5.13 M | 19.03 B |
| Total Asset | 63.95 M | 29.47 B |
| Retained Earnings | (58.5 M) | 9.33 B |
| Working Capital | 24.4 M | 1.48 B |
| Net Asset | 63.95 M |
Note: Acquisition by Upton Richard A of 5000 shares of Carmell Therapeutics at 0.4672 subject to Rule 16b-3 [view details]
Carmell Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Carmell . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 37417.67 | |||
| Daily Balance Of Power | 0.3333 | |||
| Rate Of Daily Change | 1.04 | |||
| Day Median Price | 0.26 | |||
| Day Typical Price | 0.25 | |||
| Period Momentum Indicator | 0.01 | |||
| Relative Strength Index | 41.67 |
About Carmell Therapeutics Buy or Sell Advice
When is the right time to buy or sell Carmell Therapeutics? Buying financial instruments such as Carmell Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Carmell Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Currency ETFs Thematic Idea Now
Alternative Currency ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Alternative Currency ETFs theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Currency ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.